Hascovir

Hascovir is an oral antiviral medication whose active ingredient is aciclovir. It is provided as tablets (strength not specified) and is marketed in the European Union as a prescription product. Aciclovir belongs to the antiviral drug class and works by inhibiting viral DNA polymerase, thereby limiting replication of herpes viruses. The medication is used to treat and prevent infections caused by herpes simplex and varicella‑zoster viruses.

Hascovir (aciclovir) is prescribed for several viral infections where herpes viruses are involved.

- Treatment of oral, genital, or facial herpes simplex virus infections. - Management of varicella‑zoster virus (shingles) in adults. - Prophylaxis of herpes zoster in immunocompromised patients, such as those undergoing chemotherapy or organ transplantation. - Reduction of viral shedding in recurrent herpes infections to lessen transmission risk. - Use in neonatal herpes infection under specialist supervision.

Side effects reported with Hascovir vary in frequency and severity, ranging from mild gastrointestinal complaints to rare but serious systemic reactions.

Common: - Nausea, vomiting, or upset stomach, typically transient. - Diarrhea or loose stools, occasionally mild. - Headache, often mild to moderate in intensity. - Dizziness, light‑headedness, or fatigue, usually temporary.

Serious: - Severe skin reactions such as rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis, which may require hospitalization. - Acute kidney injury indicated by reduced urine output or rising serum creatinine, potentially leading to renal failure. - Neurological effects including confusion, hallucinations, or seizures, especially in patients with renal impairment. - Blood dyscrasias such as neutropenia or thrombocytopenia, which can increase infection risk.

When prescribing Hascovir, clinicians should consider several precautionary measures to ensure safe use.

- Check renal function and adjust dose if kidney impairment is present. - Watch for hypersensitivity reactions, especially rash or fever. - Use caution in immunocompromised patients due to higher infection risk. - Consider pregnancy and breastfeeding status; safety data are limited. - Review other drugs that affect aciclovir elimination, such as probenecid. - Avoid if the patient has known allergy to aciclovir.

Hascovir may interact with other medicines, influencing its effectiveness or safety.

Avoid: - Co‑administration with other nephrotoxic agents such as aminoglycosides, which can increase kidney risk. - Use with other antiviral drugs that share similar metabolic pathways, potentially altering plasma levels.

Use with caution: - Probenecid, which reduces aciclovir renal clearance and may require dose adjustment. - Cimetidine, which can increase aciclovir concentrations. - NSAIDs, especially high‑dose ibuprofen, may enhance renal toxicity. - Immunosuppressants like cyclosporine, where infection risk may be heightened. - Live vaccines, as antiviral therapy could affect vaccine efficacy.